Recently, German medical technology company CryoTherapeutics announced the completion of a $5.2 million Series B financing. The leading investors are Creathor Venture, NRW.BANK, Peppermint CBF, High-Tech Gründerfonds (HTGF), Getz Brothers, Kreditanstalt für Wiederaufbau (KfW) and several other famous angel investors. Cardiovascular disease is the single single cause of death in Western society. In Germany, more than 300,000 people have been affected by heart disease. In Europe, the figure is 1.6 million and the United States is 1.2 million. Emergency treatment for heart disease is a market with a potential value of up to 1 billion euros, which is where CryoTherapeutics wants to make a difference. Founded in the winter of 2009, CryoTherapeutics is a group of consecutive entrepreneurs from the US, UK and Canada. The company is committed to the development and application of a suite of treatments for patients with acute coronary heart disease and myocardial infarction. This is called cryotherapy. Unlike other traditional technologies, it is predicted that cryotherapy can help many patients no longer use vascular stents. This financing will help CryoTherapeutics to occupy the European market as soon as possible. And their approach is very special: put equipment in each clinic to show the good results of their products to visiting patients. Dr. John Yianni, CEO and founder of the company, said: "We are very happy to get this financing. With this money, there will be more clinics to showcase our products." Dehydrated Garlic Powder,Dried Minced Garlic,Dry Garlic Powder,Dehydrated Garlic shandong changrong international trade co.,ltd. , http://www.changronggarliccn.com